Acceptability, feasibility and cost of point-of-care testing for sexually transmitted infections in adolescent health services in Cape Town, South Africa

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10275700

Enrollment

400

Registered

2024-01-09

Start date

2017-02-23

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Testing and treatment of chlamydia and gonorrhoea using molecular point of care testing Infections and Infestations

Interventions

Background Young people (YP) in southern Africa are at substantial risk of HIV and sexually transmitted infections (STIs). Despite the epidemiological and biological link between STIs and HIV transmis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged between 15 and 23 years old 2. Willing and able to provide signed informed consent/assent for the study 3. Sexual activity within the past two years 4. Willing to wait for results, receive results by text/phone call, or return the following day for results

Exclusion criteria

Exclusion criteria: 1. Treatment for STI or presumed STI in the past 21 days 2. Has any condition that, in the opinion of the investigator, would preclude informed consent or make study participation unsafe 3. Appears psychologically unstable, intoxicated or under the influence of alcohol or other drugs at the time of informed consent

Design outcomes

Primary

Measure	Time frame
1. To evaluate the uptake of an STI test and treat programme for adolescents (aged 15-23 years) at a stand-alone youth clinic compared to a mobile clinic serving two peri-urban areas in Cape Town, South Africa. Participants will be offered free STI testing for chlamydia (CT) and gonorrhoea (NG) using a GeneXpert, a molecular point-of-care test that can detect CT/NG within 90 minutes. 2. To assess the acceptability of an STI test and treat programme amongst adolescents (aged 15-23 years) using a self-administrated paper-based questionnaire where participants rate the STI test and treat services by answering Likert-type scale questions (including how helpful the service was, whether they would use this service if it were more widely available and if participants experienced any negative consequences as a result of using the service). 3. To establish participant characteristics and site of testing associated with uptake of STI testing and treatment though a descriptive analysis of participant demographic details, disaggregated by site.	—

Measure

Time frame

1. To evaluate the uptake of an STI test and treat programme for adolescents (aged 15-23 years) at a stand-alone youth clinic compared to a mobile clinic serving two peri-urban areas in Cape Town, South Africa. Participants will be offered free STI testing for chlamydia (CT) and gonorrhoea (NG) using a GeneXpert, a molecular point-of-care test that can detect CT/NG within 90 minutes. 2. To assess the acceptability of an STI test and treat programme amongst adolescents (aged 15-23 years) using a self-administrated paper-based questionnaire where participants rate the STI test and treat services by answering Likert-type scale questions (including how helpful the service was, whether they would use this service if it were more widely available and if participants experienced any negative consequences as a result of using the service). 3. To establish participant characteristics and site of testing associated with uptake of STI testing and treatment though a descriptive analysis of participant demographic details, disaggregated by site.

—

Secondary

Measure	Time frame
Establish the proportion of participants testing positive for chlamydia and/or gonorrhoea and the participant and site characteristics associated with positivity measured using the recorded results after the intervention	—

Countries

South Africa

Contacts

Public ContactCarey Pike

carey.pike@hiv-research.org.za+27 (0) 21 301 2020

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026